keyword
MENU ▼
Read by QxMD icon Read
search

aripiprazol

keyword
https://www.readbyqxmd.com/read/29127503/relationships-between-low-grade-peripheral-inflammation-and-psychotropic-drugs-in-schizophrenia-results-from-the-national-face-sz-cohort
#1
G Fond, N Resseguier, F Schürhoff, O Godin, M Andrianarisoa, L Brunel, E Bulzacka, B Aouizerate, F Berna, D Capdevielle, I Chereau, T D'Amato, C Dubertret, J Dubreucq, C Faget, F Gabayet, C Lançon, P M Llorca, J Mallet, D Misdrahi, C Passerieux, R Rey, A Schandrin, M Urbach, P Vidailhet, L Boyer, M Leboyer
Low-grade inflammation has repeatedly been associated with schizophrenia (SZ) and in particular with cognitive impairment. Female gender, overweight and tobacco smoking have been suggested as risk factors to increase inflammation while preclinical inconsistent findings have been found regarding the association with psychotropic drugs. The aim of this study was to explore if psychotropic drugs were associated with inflammation in SZ and to determine which psychotropic drug was associated with inflammation in stable SZ subjects while considering clinical confounding factors...
November 10, 2017: European Archives of Psychiatry and Clinical Neuroscience
https://www.readbyqxmd.com/read/29110651/variability-in-market-uptake-of-psychotropic-medications-in-europe-reflects-cultural-diversity
#2
J M Hoebert, A K Mantel-Teeuwisse, H G M Leufkens, L van Dijk
BACKGROUND: In the last 20-30 years, many international studies have found substantial differences in the use of (older) psychotropic medication between European countries. The majority mentioned an important role for attitudes and beliefs towards psychotropic medication. So far, no studies have looked into the effects of cultural diversity on the use of new medications entering the market. As national cultures relate deeply to held values regarding, for example, what is seen as effective versus ineffective or safe versus dangerous, (cultural) diversity in decision making around the role of new medications in clinical practice may already be expected from the first day after market authorization...
November 6, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/29110139/the-place-of-antipsychotics-in-the-therapy-of-anxiety-disorders-and-obsessive-compulsive-disorders
#3
REVIEW
Baptiste Pignon, Chloé Tezenas du Montcel, Louise Carton, Antoine Pelissolo
PURPOSE OF REVIEW: The purpose of this review was to assess and present the findings up to this date on the efficacy of antipsychotics in the treatment of generalized anxiety disorders (GAD), social anxiety disorders (SAD), panic disorders (PD), and obsessive-compulsive disorders (OCD), mostly based on published randomized controlled trials (RCTs) or on open-label studies when RCT were lacking. RECENT FINDINGS: Quetiapine could be recommended in patients with GAD...
November 7, 2017: Current Psychiatry Reports
https://www.readbyqxmd.com/read/29100151/aripiprazole-relieves-motivational-anhedonia-in-rats
#4
Simona Scheggi, Teresa Pelliccia, Carla Gambarana, Maria Graziella De Montis
BACKGROUND: Anhedonia is considered a relevant feature in depression and psychosis, characterized by poor treatment outcome, and associated with deficits in mesolimbic dopaminergic responsiveness. Clinical studies suggest the potential utility of aripiprazole as adjunctive therapy for resistant depression. Since aripiprazole can stabilize the dopaminergic system, in search of tailored therapeutic strategies for reward dysfunctions, we investigated whether the drug restored motivation toward positive stimuli in a rat model...
October 20, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29089771/a-multicenter-open-label-pilot-study-evaluating-the-functionality-of-an-integrated-call-center-for-a-digital-medicine-system-to-optimize-monitoring-of-adherence-to-oral-aripiprazole-in-adult-patients-with-serious-mental-illness
#5
Alex Kopelowicz, Ross A Baker, Cathy Zhao, Claudette Brewer, Erica Lawson, Timothy Peters-Strickland
BACKGROUND: Medication nonadherence is common in the treatment of serious mental illness (SMI) and leads to poor outcomes. The digital medicine system (DMS) objectively measures adherence with oral aripiprazole in near-real time, allowing recognition of adherence issues. This pilot study evaluated the functionality of an integrated call center in optimizing the use of the DMS. MATERIALS AND METHODS: An 8-week, open-label, single-arm trial at four US sites enrolled adults with bipolar I disorder, major depressive disorder, and schizophrenia on stable oral aripiprazole doses and willing to use the DMS (oral aripiprazole + ingestible event marker [IEM], IEM-detecting skin patch, and software application)...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29079503/role-of-dopamine-on-functional-recovery-in-the-contralateral-hemisphere-after-focal-stroke-in-the-somatosensory-cortex
#6
Kisho Obi, Izuki Amano, Yusuke Takatsuru
Functional recovery after a stroke is important for patients' quality of life. Not only medical care during the acute phase, but also rehabilitation during the chronic phase after a stroke is important. However, the mechanisms underlying functional recovery, particularly the chronic phase after stroke, are still not fully understood. Thus, further basic study on brain after focal stroke is necessary. In this study, we found that the concentration of dopamine (DA) increased during first week after a stroke in the hemisphere contralateral in the site of stroke by in vivo microdialysis...
October 24, 2017: Brain Research
https://www.readbyqxmd.com/read/29077621/a-systematic-review-of-atypical-antipsychotics-in-chronic-pain-management-olanzapine-demonstrates-potential-in-central-sensitization-fibromyalgia-and-headache-migraine
#7
Xavier F Jimenez, Tharani Sundararajan, Edward C Covington
INTRODUCTION: Many psychopharmacologic agents are used as primary or adjunct agents in pain management. Atypical antipsychotics (AAs) have also been used as adjuncts in pain management regimens in a variety of manners; however, their efficacy in this capacity is unclear. METHODS: A systematic review of all studies examining AA use for pain was conducted. Three literature databases were utilized to search for word combinations of "pain" and a variety of commonly-prescribed AAs (olanzapine, quetiapine, risperidone, aripiprazole, ziprasidone, clozapine, paliperidone, iloperidone, lurasidone)...
October 26, 2017: Clinical Journal of Pain
https://www.readbyqxmd.com/read/29075885/long-term-metabolic-effects-of-aripiprazole-ziprasidone-and-quetiapine-a-pragmatic-clinical-trial-in-drug-na%C3%A3-ve-patients-with-a-first-episode-of-non-affective-psychosis
#8
Javier Vázquez-Bourgon, Rocío Pérez-Iglesias, Víctor Ortiz-García de la Foz, Paula Suárez Pinilla, Álvaro Díaz Martínez, Benedicto Crespo-Facorro
INTRODUCTION: The use of second-generation antipsychotics (SGA) has been associated with metabolic changes. However, there are differences in the metabolic profile between SGAs. We have previously observed that ziprasidone had a more benign early metabolic profile compared to aripiprazole and quetiapine. However, a long-term follow-up is preferred to detect clinically relevant impairment in metabolic parameters. We aimed to compare the effect of aripiprazole, ziprasidone, and quetiapine on metabolic measures in first-episode non-affective psychosis patients after 1 year of treatment...
October 26, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/29075309/weight-changes-before-and-after-lurasidone-treatment-a-real-world-analysis-using-electronic-health-records
#9
Jonathan M Meyer, Daisy S Ng-Mak, Chien-Chia Chuang, Krithika Rajagopalan, Antony Loebel
BACKGROUND: Severe and persistent mental illnesses, such as schizophrenia and bipolar disorder, are associated with increased risk of obesity compared to the general population. While the association of lurasidone and lower risk of weight gain has been established in short and longer-term clinical trial settings, information about lurasidone's association with weight gain in usual clinical care is limited. This analysis of usual clinical care evaluated weight changes associated with lurasidone treatment in patients with schizophrenia or bipolar disorder...
2017: Annals of General Psychiatry
https://www.readbyqxmd.com/read/29073754/hiccup-due-to-aripiprazole-plus-methylphenidate-treatment-in-an-adolescent-with-attention-deficit-and-hyperactivity-disorder-and-conduct-disorder-a-case-report
#10
Meryem Ozlem Kutuk, Gulen Guler, Ali Evren Tufan, Ozgur Kutuk
Our case had hiccups arising in an adolescent with the attention deficit and hyperactivity disorder (ADHD) and conduct disorder (CD) after adding aripiprazole treatment to extended-release methylphenidate. Actually, antipsychotics are also used in the treatment of hiccups, but studies suggest that they can cause hiccups as well. Within 12 hours of taking 2.5 mg aripiprazole added to extended-release methylphenidate at a dose of 54 mg/day, 16-year-old boy began having hiccups in the morning, which lasted after 3-4 hours...
November 30, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29069975/the-combination-of-escitalopram-and-aripiprazole-investigation-of-psychomotor-effects-in-rats
#11
Roger Hudson, Yan Zhou, Francesco Leri
Pre-clinical and clinical evidence suggests that the antidepressant efficacy of the selective serotonin reuptake inhibitor escitalopram can be enhanced by the dopamine and serotonin partial agonist aripiprazole. Given the range of possible neurochemical interactions between these drugs, the current study investigated whether aripiprazole alters the hedonic and psychomotor effects of escitalopram. Male Sprague Dawley rats ( n=116) received 10 mg/kg/day escitalopram (subcutaneous), 2 mg/kg/day aripiprazole (subcutaneous), or combined aripiprazole + escitalopram, and were tested for consumption of incentive nutritional stimuli (high-fructose corn syrup and chow), stereotypy and locomotor activity...
October 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29059134/aripiprazole-for-post-traumatic-stress-disorder-a-systematic-review
#12
Sara R Britnell, Anna D Jackson, Jamie N Brown, Bruce P Capehart
OBJECTIVE: The aim of this study was to review the safety and efficacy of aripiprazole as monotherapy and adjunct therapy for the treatment of post-traumatic stress disorder (PTSD). METHODS: A search of both MEDLINE (1956 to May 2017) and EMBASE (1957 to May 2017) was conducted using the terms "aripiprazole" and "post-traumatic stress disorder," "posttraumatic stress disorder," or "PTSD." Studies evaluating the primary endpoint of PTSD in patients taking aripiprazole as monotherapy or adjunct therapy were analyzed for relevance...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29057674/all-cause-hospitalization-and-associated-costs-in-patients-with-schizophrenia-or-bipolar-disorder-initiating-long-acting-injectable-antipsychotics
#13
Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya, Michael S Broder
OBJECTIVE: To compare all-cause hospitalization and associated costs among patients with schizophrenia or bipolar disorder (BD) treated with long-acting injectable antipsychotics (LAIs). METHODS: Truven MarketScan® Medicaid claims database was used to identify patients with schizophrenia; MarketScan® Medicaid and commercial claims databases to identify BD. Adult patients with ≥1 LAI claim from 01/01/2013-06/30/2014 (ID period) were identified. The first day of LAI initiation was the index date; patients were followed for ≥1 year...
October 23, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29045307/prevalence-of-antipsychotic-treated-patients-in-a-cohort-of-adult-addicted-patients
#14
Hélène Peyrière, Caroline Diot, Erika Nogue, Marie Verschave, Morgan Laure, Marie-Christine Picot, Pierre Petit, Hélène Donnadieu-Rigole, Yves Leglise
PURPOSE: The objective of this cross-sectional study was to describe and estimate the prevalence of antipsychotics (AP) in a cohort of addicted patients, and to compare the profiles of addictive patients receiving AP or not. METHODS: We included all adult patients seen at the addiction care center of Montpellier University Hospital, between January 1, 2015, and March 31, 2015. Demographic, clinical, and therapeutic data were collected from the patients' medical records...
October 17, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29040153/vortioxetine-and-aripiprazole-combination-in-treatment-resistant-obsessive-compulsive-disorder-a-case-report
#15
Domenico De Berardis, Luigi Olivieri, Francesco Nappi, Gabriella Rapini, Federica Vellante, Ilaria Matarazzo, Nicola Serroni, Massimo Di Giannantonio
No abstract text is available yet for this article.
October 16, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29039241/aripiprazole-long-acting-injection-a-mirror-image-study-of-its-effects-on-hospitalisation-at-one-year
#16
David M Taylor, Anna Sparshatt, Fahima Amin, Ian Osborne, Olubanke Dzahini, Gwenllian Hughes, Catrin Fischetti
Second generation antipsychotic long-acting injections have a greater cost than older depots. Their cost-effectiveness has yet to be established. We conducted a non-interventional, observational, follow-up of patients prescribed aripiprazole long-acting injection in two centres using a mirror image method. Data were available for 160 patients consecutively prescribed aripiprazole long-acting injection, of whom 30 were not included in the analysis (21 forensic patients, five incomplete data and four lost to follow-up)...
October 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29034139/aripiprazole-induced-neutropenia-in-a-seven-year-old-male-a-case-report
#17
Muhammad Hassan Majeed, Ali Ahsan Ali
Blood dyscrasias are the widely known side effect of the second-generation antipsychotic medications. Aripiprazole rarely causes hematological side effects and it is considered relatively safe. We present the case report of a seven-year-old male who developed acute neutropenia a week after starting aripiprazole. His absolute neutrophil count (ANC) arose spontaneously once the medication was stopped. Clinicians should periodically check ANC in the patients taking aripiprazole as neutropenia could be lethal in extreme cases...
August 11, 2017: Curēus
https://www.readbyqxmd.com/read/29033643/dandy-walker-malformation-presenting-with-affective-symptoms
#18
Mert Batmaz, Zeynep Ezgi Balçik, Ürün Özer, Burcu Hamurişçi Yalçin, Şakir Özen
Dandy-Walker malformation is defined by enlarged posterior fossa, cystic dilatation of the fourth ventricle, and cerebellar hypoplasia. Although developmental delay and mental retardation are common in Dandy-Walker malformation cases, other comorbid psychiatric conditions have been rarely reported. There are limited numbers of case reports about comorbidity of bipolar disorder with Dandy-Walker malformation in the literature. Herein, a Dandy-Walker malformation case presenting affective symptoms is reported, and psychiatric symptoms which might be seen in this rare malformation are discussed along with diagnosis, treatment, and follow-up processes...
September 2017: Noro Psikiyatri Arsivi
https://www.readbyqxmd.com/read/29028689/effective-switch-from-clozapine-to-aripiprazole-in-treatment-resistant-schizophrenia-and-comorbid-alcohol-use-disorder
#19
Robert J Feeley, Bachaar Arnaout, Gihyun Yoon
No abstract text is available yet for this article.
October 12, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29017334/brexpiprazole-a-new-leaf-on-the-partial-dopamine-agonist-branch
#20
Judy Hope, David Castle, Nicholas A Keks
OBJECTIVES: Brexpiprazole is a new dopamine partial agonist antipsychotic in the same class as aripiprazole. This paper will briefly review brexpiprazole and compare it with aripiprazole. CONCLUSIONS: Brexpiprazole and aripiprazole are both partial agonists at dopamine D2, and serotonin 5-HT1A and antagonists at serotonin 5-HT2A and noradrenergic α1B receptors. However, the two drugs are significantly different in potencies at various receptors; neurochemical profiles predict that brexpiprazole may be comparable with aripiprazole in its antipsychotic efficacy but may cause less akathisia, extrapyramidal side effects (EPS) and activation...
October 1, 2017: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
keyword
keyword
35999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"